BJ DIGITAL (06188) issues a profit warning, expecting a net loss attributable to shareholders of no more than 110 million yuan for the interim period.
Disan Communication (06188) announced that the Group expects to report a net loss attributable to the parent company owners of no more than RMB 110 million for the six months ending June 30, 2026, representing an increase in losses compared to approximately RMB 76.64 million for the same period in 2025. The change is primarily due to the continuous rise in arrival prices leading to increased product prices, which has resulted in decreased market demand. The persistently sluggish offline market environment has led to a reduction in the scale of the Group's offline channel promotion business and a decline in the overall gross profit margin.
BJ DIGITAL (06188) announced that the group expects to report a net loss attributable to the company's shareholders of no more than RMB 110 million for the six months ending June 30, 2026, marking an increase in loss compared to approximately RMB 76.64 million for the same period in 2025. This change is primarily due to the continuous rise in procurement prices leading to increased product prices, which has resulted in reduced market demand. The persistently sluggish offline market environment has led to a decrease in the scale of the group's offline channel promotion business and an overall decline in gross profit margins.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276): Tian Fei has been appointed as the Secretary of the Board.

Jiangsu Hengrui Pharmaceuticals (01276) plans to repurchase 1 billion to 2 billion yuan of A-shares for the A-share employee stock ownership plan.

The world's first mRNA tumor vaccine meets phase three standards, and Sidis Pharmaceuticals (01244) rises 17% as it is re-evaluated against international benchmarks.
Jiangsu Hengrui Pharmaceuticals (01276): Tian Fei has been appointed as the Secretary of the Board.

Jiangsu Hengrui Pharmaceuticals (01276) plans to repurchase 1 billion to 2 billion yuan of A-shares for the A-share employee stock ownership plan.

The world's first mRNA tumor vaccine meets phase three standards, and Sidis Pharmaceuticals (01244) rises 17% as it is re-evaluated against international benchmarks.

RECOMMEND





